Phosphogliv capsules, 96pcs

Composition

Per capsule:

Active ingredients: Phospholipids (lipoid C 80) (in terms of 100% substance) (the main component is phosphatidylcholine 73-79%) – 65.0 mg, sodium glycyrrhizinate (trisodium salt of glycyrrhizic acid) – 35.0 mg.

Excipients: microcrystalline cellulose-141.2 mg, calcium carbonate-204.7 mg, calcium stearate-0.9 mg, talc-7.7 mg, colloidal silicon dioxide (aerosil) – 5.5 mg.

Solid gelatin capsules -96.0 mg

Housing: the dye sunset yellow (E 110) – 1,0000%, titanium dioxide (E 171) – 1,0000%, gelatin – 100.0%;

lid: titanium dioxide (E 171) – of 0.2000%, dye iron oxide black (E 172) – 3,5000%, gelatin – 100.0%. ]

Pharmacological properties

Pharmacotherapeutic group: hepatoprotective medicine

ATX code: A 05 VA

Pharmacological properties.

Combined product. It has a membrane-stabilizing, hepatoprotective effect.

Pharmacodynamics

Combined product. It has hepatoprotective, membrane-stabilizing and antiviral effects.

Glycyrrhizic acid has a hepatoprotective effect due to its antioxidant, anti-inflammatory effects, as well as its effect on fibrogenesis.

Antioxidant effect. Glycyrrhizic acid binds free oxygen radicals and inhibits enzymes that initiate lipid peroxidation (LPO) in hepatocytes.

Anti-inflammatory effect. Glycyrrhizic acid reduces inflammation by inhibiting the NF-kB and TLR4 signaling pathways; inhibiting the production of pro-inflammatory cytokines (TNF-α, IL-1, IL-6, IL-8); and stimulating the production of anti-inflammatory cytokines (IL-2, IL-10, IL-12). Glycyrrhizic acid inhibits 11b-oxysteroid dehydrogenase, which contributes to an increase in endogenous cortisol in the blood (pseudocorticosteroid effect).

The effect on fibrogenesis is associated with a decrease in the expression of the type 1 collagen gene and a decrease in the production of collagen by stellate liver cells (Ito cells), as well as the destruction of activated Ito cells through the natural killer system, which helps slow down the progression of fibrosis.

Inhibits the reproduction of viruses in the liver and other organs by stimulating the production of interferons, increasing phagocytosis, and increasing the activity of natural killer cells.

With skin lesions, due to its anti-inflammatory action, it limits the spread of the process and contributes to the regression of the disease.

Phosphatidylcholine (the Active ingredient of phospholipids) is the main structural element of cellular and intracellular membranes, restores their structure and functions in case of damage, having a membrane-stabilizing effect. It normalizes protein and lipid metabolism, prevents the loss of enzymes and other active substances by hepatocytes, and helps restore liver function.

Pharmacokinetics

Glycyrrhizic Acid

After oral use in the intestine, under the influence of the enzyme β-glucuronidase, produced by bacteria of normal microflora, glycyrrhizic acid forms an active metabolite-β-glycyrrhetic acid, which is absorbed into the systemic circulation. In the blood, beta-glycyrrhetic acid binds to albumin and is almost completely transported to the liver. The release of β-glycyrrhetoic acid occurs mainly with bile, in the residual amount – with urine.

According to experimental data, phospholipids improve the lipophilic properties of glycyrrhizic acid, increasing the intensity and rate of its absorption by more than 2 times.

Phosphatidylcholine

More than 90% of oral phospholipids are absorbed in the small intestine. Most of them are broken down by phospholipase A to 1-acetyl-lysophosphatidylcholine,50% of which undergoes reverse acetylation to polyunsaturated phosphatidylcholine during absorption in the intestinal mucosa. Polyunsaturated phosphatidylcholine with the lymph flow enters the blood, from where, mainly in the form associated with high-density lipoproteins, it enters the liver. Pharmacokinetics in humans were studied using dilenoleylphosphatidylcholine with a radioactive label-3 H (choline part) and 14C (linoleic acid residue). The maximum concentration of 3 H is reached in 6-24 hours, amounting to 19.9% of the prescribed dose; 14 C-in 4-12 hours, amounting to 27.9%. The half-life of the choline component is 66 hours, and that of the linoleic acid residue is 32 hours. In the feces,2% 3 N and 4.5% 14 S are detected; in the urine,6% 3 N and a minimum amount of 14 S. Both isotopes are absorbed in the intestine by more than 90%.

Indications

-Fatty liver degeneration (hepatosis), alcoholic, toxic, including medicinal, liver damage.

– As part of the complex therapy of viral hepatitis, cirrhosis of the liver and psoriasis.

Use during pregnancy and lactation

The drug is contraindicated during pregnancy and lactation (there are insufficient data on efficacy and safety).

Contraindications

-Hypersensitivity to glycyrrhizic acid, phosphatidylcholine or other components of the drug;

– Antiphospholipid syndrome;

– Pregnancy (there are insufficient data on efficacy and safety);

– Breast-feeding period (there are insufficient data on efficacy and safety);

– Children under 12 years of age (there are insufficient data on efficacy and safety).

With caution.

In patients with portal hypertension. In patients with arterial hypertension.

If you have these diseases, you should consult a doctor before taking the drug.

Side effects

Usually, the drug Phosphogliv is well tolerated, side effects develop very rarely, according to post-marketing surveillance-the frequency is < 1/10 000.

Allergic reactions: skin rash, difficulty in nasal breathing, conjunctivitis, cough.

From the cardiovascular system: transient increased blood pressure, peripheral edema.

From the digestive system: dyspepsia (belching, nausea, bloating), abdominal discomfort.

If you experience these symptoms, you should stop taking the drug and consult your doctor.

How to take, course of use and dosage

Take orally, during meals, without chewing, with a small amount of liquid.

The recommended dosage regimen for adults and children over 12 years of age is 2 capsules 3 times a day. The duration of application can be up to 6 months, on average-3 months.

Description

Capsules are solid gelatin No. 0, the capsule body is orange, the lid is black. The content of the capsule is a granular powder from white with a slightly yellowish tinge to light yellow, with a faint specific smell.

Special instructions

If blood pressure increases, stop taking the drug and consult a doctor.

Influence on the ability to drive vehicles and mechanisms.

The drug does not adversely affect the ability to drive vehicles and perform other work that requires increased concentration of attention and speed of psychomotor reactions.

Storage conditions

Store at a temperature not exceeding 25 °C.

Keep out of the reach of children.

Shelf

life is 3 years. Do not use the product after the expiration date.

Active ingredient

Glycyrrhizic acid, Phospholipids

Dosage form

Capsules